Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models

被引:83
作者
Chung, YL
Troy, H
Banerji, U
Jackson, LE
Walton, MI
Stubbs, M
Griffiths, JR
Judson, IR
Leach, MO
Workman, P
Ronen, SM
机构
[1] St George Hosp, Sch Med, Dept Basic Med Sci, Canc Res UK Biomed Magnet Resonance Res Grp, London SW17 0RE, England
[2] Inst Canc Res, Canc Res UK Ctr Canc Therapeut, Surrey, England
[3] Inst Canc Res, Canc Res UK Clin Magnet Resonance Res Grp, Sutton, Surrey, England
[4] Royal Marsden Hosp, Sutton, Surrey, England
关键词
D O I
10.1093/jnci/djg084
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. 17-Allylamino,17-demethoxygeldanamycin (17AAG) is a novel anticancer drug that inhibits heat shock protein 90 (Hsp90), resulting in proteasomal degradation of several oncogenic proteins. We used phosphorus magnetic resonance spectroscopy (P-31-MRS) to determine whether 17AAG treatment leads to alterations in phospholipids that could serve as pharmacodynamic markers for tumor response to 17AAG. Methods: HCT116, HT29, and SW620 colon cancer cells were treated with 17AAG, and extracts were examined by P-31-MRS. HT29 cells were also treated with the active metabolite of 17AAG, 17-amino,17-demethoxygeldanamycin (17AG), or the inactive 17AAG analog NSC683666. MF-1 nude mice carrying HT29 xenografts were examined using in vivo P-31-MRS before and after 17AAG treatment; xenograft. 3 tumor extracts were examined by P-31-MRS and proton MRS (H-1-MRS). Hsp90 client protein expression was determined by using western blots. Two-tailed t tests were used to compare metabolite concentrations and ratios, and a Mann-Whitney U test was used to compare proportions. All statistical tests were two-sided. Results: 17AAG treatment led to statistically significantly increased phosphocholine levels in all three cell lines (P =.02). 17AG treatment also increased phosphocholine levels in HT29 cells, whereas NSC683666 had no effect. The phosphomonoester/phosphodiester ratio was statistically significantly increased in the HT29 xenografts after 17AAG treatment relative to the pretreatment ratio (P =.02), whereas no statistically significant change was observed after vehicle treatment (P =.62). Statistically significant increases in phosphocholine, phosphoethanolamine, and valine levels were also observed in tumor extracts treated with 17AAG. Conclusions: Inhibition of Hsp90 by 17AAG resulted in altered phospholipid metabolism in cultured tumor cells and in tumor xenografts. The increases observed in phosphocholine and phosphomonoester levels suggest that these metabolites may have the potential to act as noninvasive pharmacodynamic markers for analyzing tumor response to treatment with 17AAG or other Hsp90 inhibitors.
引用
收藏
页码:1624 / 1633
页数:10
相关论文
共 61 条
[51]   AN ASSESSMENT OF P-31 MRS AS A METHOD OF MEASURING PH IN RAT-TUMORS [J].
STUBBS, M ;
BHUJWALLA, ZM ;
TOZER, GM ;
RODRIGUES, LM ;
MAXWELL, RJ ;
MORGAN, R ;
HOWE, FA ;
GRIFFITHS, JR .
NMR IN BIOMEDICINE, 1992, 5 (06) :351-359
[52]   PRECLINICAL PHARMACOLOGICAL EVALUATION OF GELDANAMYCIN AS AN ANTITUMOR AGENT [J].
SUPKO, JG ;
HICKMAN, RL ;
GREVER, MR ;
MALSPEIS, L .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 36 (04) :305-315
[53]   P-31 NMR-SPECTROSCOPY OF A XENOGRAFTED HYPOPHARYNX CARCINOMA - EFFECTS OF TUMOR-GROWTH AND TREATMENT WITH CISPLATIN ON THE TUMOR PHOSPHORUS-METABOLISM, HISTOLOGY AND CYTOKINETICS [J].
TAUSCHTREML, R ;
BAUMGART, F ;
ZIESSOW, D ;
KOPFMAIER, P .
NMR IN BIOMEDICINE, 1992, 5 (03) :127-136
[54]   Simultaneous extraction of cellular lipids and water-soluble metabolites: Evaluation by NMR spectroscopy [J].
Tyagi, RK ;
Azrad, A ;
Degani, H ;
Salomon, Y .
MAGNETIC RESONANCE IN MEDICINE, 1996, 35 (02) :194-200
[55]  
*UK COORD COMM CAN, 1998, UKC CCR GUID WELF AN, V77, P1
[56]   Phosphorylation of p42/44MAPK by various signal transduction pathways activates cytosolic phospholipase A2 to variable degrees [J].
van Rossum, GSAT ;
Klooster, R ;
van den Bosch, H ;
Verkleij, AJ ;
Boonstra, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (31) :28976-28983
[57]   ACCURATE QUANTIFICATION OF INVIVO P-31 NMR SIGNALS USING THE VARIABLE PROJECTION METHOD AND PRIOR KNOWLEDGE [J].
VANDERVEEN, JWC ;
DEBEER, R ;
LUYTEN, PR ;
VANORMONDT, D .
MAGNETIC RESONANCE IN MEDICINE, 1988, 6 (01) :92-98
[58]  
VAUPEL P, 1989, CANCER RES, V49, P6449
[59]   Challenges of PK/PD measurements in modern drug development [J].
Workman, P .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (16) :2189-2193
[60]   Translating basic cancer research into new cancer therapeutics [J].
Workman, P ;
Kaye, SB .
TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) :S1-S9